# GELS — Gelteq Ltd · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** GELS  
**Sources:** 13  
**Published:** 2026-11-01  
**Canonical:** https://app.k3vl4r.com/research/deep-research-gels-gelteq-ltd-catalysts-narrative-risks-10479

---

## Snapshot (as of the latest available data, 30 Oct 2026)

Gelteq Limited (NASDAQ: GELS) is a Melbourne-based, U.S.- and Australia-listed micro-cap biotechnology company developing a proprietary gel-based oral delivery platform for human and animal health, operating on a white-label licensing model [[3]](https://tickernerd.com/stock/gels-forecast/), [[15]](https://stockanalysis.com/stocks/gels/). As of 30 Oct 2026, the stock traded around $0.49 with a market capitalization of roughly $5.2–5.5M, down ~3% on the day, and trading far below its 52-week high of ~$2.01 [[3]](https://tickernerd.com/stock/gels-forecast/), [[12]](https://finance.yahoo.com/quote/GELS/), [[15]](https://stockanalysis.com/stocks/gels/). It has essentially no analyst coverage and no price target [[3]](https://tickernerd.com/stock/gels-forecast/), [[15]](https://stockanalysis.com/stocks/gels/).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-gels-gelteq-ltd-catalysts-narrative-risks-10479 (free to sign up)._